Journal of Cutaneous and Aesthetic Surgery
Print this page
Email this page
Small font size
Default font size
Increase font size
Home About us Current issue Archives Instructions Submission Subscribe Editorial Board Partners Contact e-Alerts Login 

   Table of Contents     
Year : 2011  |  Volume : 4  |  Issue : 2  |  Page : 154-155
Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide

Department of Dermatology and STD, University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Shahadara, Delhi, India

Click here for correspondence address and email

Date of Web Publication17-Sep-2011

How to cite this article:
Gandhi V, Naik G, Verma P. Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide. J Cutan Aesthet Surg 2011;4:154-5

How to cite this URL:
Gandhi V, Naik G, Verma P. Eccrine hidrocystoma successfully treated with topical synthetic botulinum peptide. J Cutan Aesthet Surg [serial online] 2011 [cited 2022 Oct 1];4:154-5. Available from:


Eccrine hidrocystomas (EHs) are benign cystic lesions of eccrine ducts that are associated with a chronic course and seasonal variations. They are more frequent in females than in males. [1] Solitary EH can be treated easily by surgical excision; however, the treatment of multiple lesions is problematic. We report a case of multiple eccrine hydrocystomas over the face, which responded completely after 4 weeks of treatment with topical Botulinum Toxin (Boxtlak-BL) like preparation.

A 60-year-old Indian lady presented with multiple papules over the cheeks since last 5-6 years, which were persistent and aggravated in summer and on exposure to heat. On local examination, there were shiny, translucent papules of 1-3 mm in diameter on the centrofacial area. On puncturing with a disposable needle, clear watery fluid came out. A skin biopsy stained with haematoxylin and eosin showed dilated cystic spaces in upper dermis [Figure 1], which were unilocular and lined by flattened squamous epithelial cells in two layers. There were no myoepithelial cells in the cyst wall. There was no evidence of decapitation secretions in the lining cells. [2] Based on clinical features and histopathology, a diagnosis of multiple EHs was made. The patient was treated with topical Boxtlak-BL twice daily and there was almost complete clearance of lesions after 4 weeks of treatment [Figure 2] and [Figure 3].
Figure 1: Dilated unilocular cystic spaces lined by two layers of squamous epithelial cells without any evidence of decapitation secretions, (H and E, ×40)

Click here to view
Figure 2: Multiple eccrine hydrocystomas over the left cheek before treatment

Click here to view
Figure 3: After 4 weeks of topical treatment with Boxtlak-BL cream

Click here to view

EH is a benign cystic condition of eccrine sweat ducts. [3] The aetiopathogenesis is still debatable. Electron microscopy has established that the cyst wall is composed of ductal cells. It is likely that obstruction of eccrine duct leads to retention of sweat causing flattening of the lining cells and cystic dilatation.

Treatment of EH is recommended for cosmetic reasons. Different modalities have been proposed with variable results, which include puncture and drainage of the cyst that gives transient improvement with an early recurrence, [4] surgical excision, [4] microdermabrasion and electrodessication with high risk of scarring, [5] pulse dye laser, [6] topical atropine [7] and scopolamine. [8] Recently EH has been treated with botulinum toxin (injectable) with good results. [9]

Botulinum toxin (Boxtlak-BL) is a potent neurotoxin that blocks cholinergic nerve terminals. It has been used in the treatment of blepharospasm, strabismus, torticollis, hemifacial spasm and other dystonias. [10] It has also been used in the treatment of hyperhidrosis [11] and facial wrinkles. Boxtlak-BL containing BoNT_L peptide significantly inhibits SNAP-25 (synaptosome-associated protein of 25 kd) [12] of SNARE complex thereby inhibiting the release of acetylcholine from vesicle within the cytoplasm of the motor nerve endings. The end result is chemodenervation of cholinergic nerves targeting the autonomic control of eccrine sweat glands.

We propose topical Botulinum toxin like peptide as a painless, non-invasive, cost-effective and safe technique for the treatment of multiple EH with excellent results.

   References Top

1.Hashimoto K, Lever WF. Tumors of skin appendages. In: Fitzpatrick TB, Eisen AZ, Wolf K Freedberg IM, Austen K. Dermatology in General Medicine. 4 th ed. New york: Mc Graw-Hill; 1983. p. 550-1.  Back to cited text no. 1
2.Klein W, Chan E, Seykora JT. Tumours of epidermal appendages. In: Eldn DE, editor. Levers histopathology of skin. 9 th ed. Philadelphia USA; Lippincott Williams and Wilkins; 2005. p. 867-926.  Back to cited text no. 2
3.Robinson AR. Hidrocystoma. J Cutan Genitourinary Dis 1893;11:292-303.  Back to cited text no. 3
4.Fariña MC, Piqué E, Olivares M, Escalonilla P, Martín L, Requena L, et al. Multiple hidrocystomas of face; Three cases. Clin Exp Dermatol 1995;20:323-7.  Back to cited text no. 4
5.Blugerman G, Sehavelzon D, D'Angelo S. Multiple eccrine hidrocystomas, A new therapeutic option with Botulinum Toxin. Dermatol Surg 2003;29:557-9.  Back to cited text no. 5
6.Tanzi E, Alster TS. Pulsed dye laser treatment of multiple eccrine hidrocystomas: A novel approach. Dermatol Surg 2001;27:898-900.  Back to cited text no. 6
7.Khunger N, Mishra S, Jain RK, Saxena S. Multiple eccrine hidrocystomas. Report of 2 cases treated unsuccessfully with atropine ointment. Indian J Dermatol Venereol Leprol 2004;70:367-9.  Back to cited text no. 7
[PUBMED]  Medknow Journal  
8.Clever HW, Shal WJ. Multiple eccrine Hidrocystomas: A nonsurgical treatment. Arch Dermatol 1991;127:422-4.  Back to cited text no. 8
9.Correia O, Duarte A, Barros A, Rocha N. Multiple Eccrine Hidrocystomas- From Diagnosis to Treatment: The role of Dermatoscopy and Botulinum Toxin: Dermatology 2009;219:77-9.  Back to cited text no. 9
10.Carruthers A, Carruthers J. History of cosmetic use of Botulinum A exotoxin. Dermatol Surg 1998;24:1168-70.   Back to cited text no. 10
11.Glogou RG. Use of hyperhidrosis with botulinum toxin. Dermatol Clin 2004;22:177-85,vii.  Back to cited text no. 11
12.Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248:3-10.  Back to cited text no. 12

Correspondence Address:
Vijay Gandhi
Department of Dermatology and STD, University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Shahadara, Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-2077.85048

Rights and Permissions


  [Figure 1], [Figure 2], [Figure 3]

This article has been cited by
1 Botulinum toxin A as monotherapy for syringoma
Josť Luis Zaldivar-Fujigaki, Lucia Achell Nava
Journal of Cosmetic Dermatology. 2021; 20(5): 1393
[Pubmed] | [DOI]
2 Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation
Iga Plachta, Marcin Kleibert, Anna M. Czarnecka, Mateusz Spalek, Anna Szumera-Cieckiewicz, Piotr Rutkowski
International Journal of Molecular Sciences. 2021; 22(10): 5077
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  

    Article Figures

 Article Access Statistics
    PDF Downloaded150    
    Comments [Add]    
    Cited by others 2    

Recommend this journal